The offering provides near-term funding but highlights ongoing financial distress with going concern doubt and Nasdaq listing issues. The 22.7% potential dilution from this offering and existing warrants could pressure the stock price, especially as the company continues to commercialize LYMPHIR without generating operating revenue.
Price Chart
Executive Summary
Citius Pharmaceuticals is raising $5 million through a registered direct offering of 4.73 million common shares and pre-funded warrants for 345,686 shares at $0.985 per share, alongside concurrent private placement of warrants. The net proceeds of $4.5 million will fund LYMPHIR commercialization and development of other product candidates.
Key Facts
- Offering 4,730,457 common shares and pre-funded warrants for 345,686 shares at $0.985 per share
- Estimated net proceeds of $4.5 million after fees and expenses
- Proceeds to be used for LYMPHIR commercialization, development initiatives, and general corporate purposes
- Company has substantial doubt about its ability to continue as a going concern
- Common stock trading below $1.00 minimum bid price requirement, received Nasdaq deficiency notice
Financial Impact
Gross proceeds of $4,999,966.29 from issuance of common stock and pre-funded warrants at $0.985 per share
Risk Factors
- Substantial doubt about the company's ability to continue as a going concern
- Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-047296 |
| Document: 0001213900-26-047296-index-headers.html | 0001213900-26-047296 |
| Document: 0001213900-26-047296-index.html | 0001213900-26-047296 |
| Document: 0001213900-26-047296.txt | 0001213900-26-047296 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.4582 | awaiting T+60 | — | $0.4490 (−2.01%) |
Aug 5, 2026 11w ago | 8-K | $0.7809 | awaiting T+60 | — | $0.4490 (−42.50%) |
Jun 3, 2026 20w ago | EFFECT | $0.5800 $0.6290 | ▼ −8.45% | ▼ −5.95% | $0.4490 (+22.59%) |
Jun 1, 2026 21w ago | 8-K | $0.6030 $0.5771 | ▼ −4.30% | ▼ −5.41% | $0.4490 (−25.54%) |
May 22, 2026 22w ago | S-3 | $0.6970 $0.6375 | ▲ +8.54% | ▲ +11.26% | $0.4490 (+35.58%) |
May 15, 2026 23w ago | 8-K | $0.5270 $0.7650 | ▼ −45.16% | ▼ −40.31% | $0.4490 (+14.80%) |
Apr 24, 2026 26w ago | 8-K | $0.6910 $0.5623 | ▲ +18.63% | ▲ +23.40% | $0.4490 (+35.02%) |
Apr 24, 2026 26w ago | 424B5 | $0.7700 $0.5455 | ▲ +29.16% | ▲ +34.24% | $0.4490 (+41.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers